Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period

BMC Endocrine Disorders

Hélio Rubens de Carvalho Nunes⁴  Altamir Santos Teixeira³  Maria Regina Moretto²  Cilmery Suemi Kurokawa²  Tamara Beres Lederer Goldberg¹  Talita Poli Biason¹ 

[1]Department of Pediatrics, Adolescent Medicine Discipline, Graduate Program in Gynecology, Obstetrics, and Mastology, Botucatu School of Medicine, São Paulo State University (UNESP), São Paulo, Brazil

[2]Clinical and Experimental Pediatrics Research Center, Department of Pediatrics, Botucatu Medical School, São Paulo State University (UNESP), São Paulo, Brazil

[3]Department of Tropical Diseases and Diagnostic Imaging, Botucatu School of Medicine, São Paulo State University (UNESP), São Paulo, Brazil

[4]Statistical Consultant, Botucatu School of Medicine, São Paulo State University (UNESP), São Paulo, Brazil

关键词: Osteoporosis;    Contraceptives;    Bone mineral content;    Bone density;    Adolescent;   

Others  :  1204255
DOI  :  10.1186/s12902-015-0012-7

 received in 2014-04-03, accepted in 2015-03-26,  发布年份 2015

【 摘 要 】

Background

Low-dose combined oral contraceptives (COCs) can interfere with bone mass acquisition during adolescence. This study aimed to evaluate bone mineral density (BMD) and bone mineral content (BMC) in female adolescents taking a standard low-dose COC (ethinylestradiol 20 μg/desogestrel 150 μg) over a 1-year period and to compare their data with those of healthy adolescents from the same age group not taking COCs.

Methods

This was a non-randomized parallel-control study with a 1-year follow-up. Sixty-seven adolescents aged from 12 to 19 years, divided into COC users (n = 41) taking 20 μg ethinylestradiol/150 μg desogestrel and COC non-user controls (n = 26), were evaluated by bone densitometry examinations at baseline and after 12 months. Comparisons between the groups at the study onset were performed using the Mann–Whitney test with the significance level fixed at 5% or p < 0.05. Comparisons between the groups at the study onset and after 12 months were based on variations in the median percentages for bone mass variables.

Results

The COC users presented with low bone mass acquisition in the lumbar spine, and had BMD and BMC median variations of 2.07% and +1.57%, respectively, between the measurements at baseline and 12 months. The control group had median variations of +12.16% and +16.84% for BMD and BMC, respectively, over the same period. The total body BMD and BMC showed similar evolutions during the study in both groups. Statistical significance (p < 0.05) was seen for the BMC percentage variation between COC users and non-users.

Conclusions

Use of a low-dose COC (ethinylestradiol 20 μg/desogestrel 150 μg) was associated with lower bone mass acquisition in adolescents during the study period.

Trial registration

Registry Number, RBR-5h9b3c.

【 授权许可】

   
2015 Biason et al.; licensee BioMed Central.

【 参考文献 】

• [1]Looker A, Marcus R, Matkovic V, Weaver C. Peak bone mass. Osteoporos Int. 2000; 11:985-1009.
• [2]Leonard MB, Zemel BS. Current concepts in pediatric bone disease. Pediatr Clin North Am. 2002; 49:143-73.
• [3]Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002; 23:279-302.
• [4]Rizzoli R, Bianchi ML, Garabédian M, McKay HA, Moreno LA. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone. 2010; 46:294-305.
• [5]Saggese G, Baroncelli GI, Bertelloni S. Osteoporosis in children and adolescents: diagnosis, risk factors, and prevention. J Pediatr Endocrinol Metab. 2001; 14:833-59.
• [6]Duren DL, Blangero J, Sherwood RJ, Seselj M, Dyer T, Cole SA et al.. Cortical bone health shows significant linkage to chromosomes 2p, 3p, and 17q in 10-year-old children. Bone. 2011; 49:1213-8.
• [7]Ma NS, Gordon CM. Pediatric osteoporosis: where are we now? J Pediatr. 2012; 161:983-90.
• [8]Hartard M, Kleinmond C, Wiseman M, Weissenbacher ER, Felsenberg D, Erben RG. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone. 2007; 40:444-50.
• [9]Chow J, Tobias JH, Colston KW, Chambers TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest. 1992; 89:74-8.
• [10]Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996; 2:1132-6.
• [11]Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21:115-37.
• [12]Taranta A, Brama M, Teti A, De Luca V, Scandurra R, Spera G et al.. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002; 30:368-76.
• [13]Viereck V, Gründker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH et al.. Raloxifene concurrently stimulates osteoprotegerin and inhibits Interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003; 88:4206-13.
• [14]Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat 23. 2010; 29:1-44.
• [15]Gai L, Jia Y, Zhang M, Gai P, Wang S, Shi H et al.. Effect of two kinds of different combined oral contraceptives use on bone mineral density in adolescent women. Contraception. 2012; 86:332-6.
• [16]Pikkarainen E, Lehtonen-Veromaa M, Möttönen T, Kautiainen H, Viikari J. Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception. 2008; 78:226-31.
• [17]Hartman LB, Monasterio E, Hwang LY. Adolescent contraception: review and guidance for pediatric clinicians. Curr Probl Pediatr Adolesc Health Care. 2012; 42:221-63.
• [18]Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al.. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11. 2002; 246:1-190.
• [19]Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44:291-303.
• [20]Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford University Press, Palo Alto, CA; 1959.
• [21]Bianchi ML, Baim S, Bishop NJ, Gordon CM, Hans DB, Langman CB et al.. Official positions of the international society for clinical densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol. 2010; 25:37-47.
• [22]Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. [http://www.ncbi.nlm.nih.gov/books/NBK56070/]
• [23]Colli AS. Crescimento e desenvolvimento físico. In: Comissão de Saúde do Adolescente da Secretaria de Estado da Saúde de São Paulo. Paris Editorial, São Paulo; 1988: p.43-57.
• [24]Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception. 1983; 27:577-90.
• [25]Polatti F, Perotti F, Filippa N, Gallina D, Nappi RE. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception. 1995; 51:221-4.
• [26]Almstedt Shoepe H, Snow CM. Oral contraceptive use in young women is associated with lower bone mineral density than that of controls. Osteoporos Int. 2005; 16:1538-44.
• [27]Cibula D, Skrenkova J, Hill M, Stepan JJ. Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. Eur J Endocrinol. 2012; 166:1003-11.
• [28]van der Sluis IM, de Muinck Keizer-Schrama SM. Osteoporosis in childhood: bone density of children in health and disease. J Pediatr Endocrinol Metab. 2001; 14:817-32.
• [29]Lash RW, Nicholson JM, Velez L, Van Harrison R, McCort J. Diagnosis and management of osteoporosis. Prim Care. 2009; 36:181-98.
• [30]Agostinho K, Di Meglio G. Low-dose oral contraceptives in adolescents: how low can you go? J Pediatr Adolesc Gynecol. 2010; 23:195-201.
• [31]Wang Q, Nicholson PH, Suuriniemi M, Lyytikäinen A, Helkala E, Alen M et al.. Relationship of sex hormones to bone geometric properties and mineral density in early pubertal girls. J Clin Endocrinol Metab. 2004; 89:1698-703.
• [32]Lattakova M, Borovsky M, Payer J, Killinger Z. Oral contraception usage in relation to bone mineral density and bone turnover in adolescent girls. Eur J Contracept Reprod Health Care. 2009; 14:207-14.
• [33]Finkelstein JW. The endocrinology of adolescence. Pediatr Clin North Am. 1980; 27:53-69.
• [34]Scholes D, Ichikawa L, LaCroix AZ, Spangler L, Beasley JM, Reed S et al.. Oral contraceptive use and bone density in adolescent and young adult women. Contraception. 2010; 1:35-40.
• [35]Trémollieres F. Impact of oral contraceptive on bone metabolism. Best Pract Res Clin Endocrinol Metab. 2013; 27:47-53.
• [36]Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception. 2006; 73:445-69.
• [37]Coutant R, de Casson FB, Rouleau S, Douay O, Mathieu E, Gatelais F et al.. Divergent effect of endogenous and exogenous Sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents. J Clin Endocrinol Metab. 2004; 89:6185-92.
• [38]Churchwell MI, Camacho L, Vanlandingham MM, Twaddle NC, Sepehr E, Delclos KB et al.. Comparison of life-stage-dependent internal dosimetry for bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of action in Sprague Dawley rats. Toxicol Sci. 2014; 139:4-20.
• [39]Erben RG, Brunner KS, Breig B. Long-term sensitivity of uterus and hypothalamus/pituitary axis to 17beta-estradiol is higher than that of bone in rats. J Bone Miner Res. 2004; 19:1827-32.
• [40]Walsh JS, Eastell R, Peel NF. Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case–control study. J Clin Endocrinol Metab. 2008; 93:1317-23.
• [41]Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010; 2010:845180.
• [42]Cromer BA, Stager M, Bonny A, Lazebnik R, Rome E, Ziegler J et al.. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004; 35:434-41.
• [43]Ishida Y, Ishida Y, Heersche JN. Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporos Int. 2002; 13:601-5.
• [44]Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J et al.. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. 2005; 192:42-7.
• [45]Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012; 86:606-21.
• [46]Guilbert ER, Brown JP, Kaunitz AM, Wagner MS, Bérubé J, Charbonneau L et al.. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception. 2009; 79:167-77.
• [47]Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in very young women using combined oral contraceptives. Contraception. 2008; 78:358-64.
• [48]Moretto de Oliveria MR, Cristiane da Silva C, Kurokawa CS, Teixeira Fortes CM, Campos Capela R, Santos Teixeira A et al.. Bone mineral density in healthy female adolescents according to age, bone age and pubertal breast stage. Open Orthop J. 2011; 5:324-30.
• [49]Fortes CM, Goldberg TB, Kurokawa CS, Silva CC, Moretto MR, Biason TP et al.. Relationship between chronological and bone ages and pubertal stage of breasts with bone biomarkers and bone mineral density in adolescents. J Pediatr (Rio J). 2014; 90:624-31.